Microsoft word - 5 essential drug list c.g.doc

1.1 General anaesthetics and oxygen
Injection, 50 mg (as hydrochloride)/ml in 10-ml vial Injection, powder for solution, 0.5 g, 1.0 g (sodium salt) in ampoules 1.2 Local anaesthetics
Injection, 0.25%, 0.5% (hydrochloride) in 10ml vial Injection for spinal anaesthesia, 0.5% (hydrochloride) in 4-ml ampoule to be mixed with 7.5% glucose solution Injection, 1%, 2% (hydrochloride) in 30ml vial injection for spinal anaesthesia, 5% (hydrochloride) in 2-ml ampoule to be mixed with 7.5% glucose solution Injection 1% Lidocaine (hydrochloride)+ Epinephrine 1:200 000 in vial; Dental cartridge 2% Lidocaine (hydrochloride) + Epinephrine 1:80 000 in 2.2ml cartridge 1.3 Preoperative medication and sedation for short-term procedures
Injection, 0.6 micrograms/ml (sulfate) in 1-ml ampoule, Tablet 1mg, Oral solution (elixir) syrup, 200 mg/5ml Injection, 5 mg/ml in 2-ml ampoule; Tablet, 5 mg Injection, 10 mg (sulfate or hydrochloride) in 1-ml ampoule Elixir or syrup, 5 mg (hydrochloride)/5ml 2. ANALGESICS, ANTIPYRETICS, NON-STEROIDAL ANTI-INFLAMMATORY

2.1 Non-opioids and non-steroidal anti-inflammatory medicines (NSAIDs)
2.2 Opioids analgesics
Injection, 10 mg in 1-ml ampoule (sulfate or hydrochloride) Injection (hydrochloride) 400 micrograms/ml; 1ml ampoule 2.4 Disease modifying agents used in rheumatoid disorders (DMARDs)
Tablet, 150 mg base (as phosphate or sulfate) 3. ANTIALLERGICS AND MEDICINES USED IN ANAPHYLAXIS
Tablet, 4 mg (hydrogen maleate); oral solution, 2mg/5ml; Injection, 10 mg/ml in 1-ml ampoule Tablet, 500 micrograms, 4 mg; Injection, 4 mg/ml (phosphate -sodium salt) in 1-ml ampoule Injection, 1 mg/ml (as hydrochloride or hydrogen tartrate) in 1-ml Powder for injection, 100 mg (as sodium succinate) in vial 4. ANTIDOTES AND OTHER SUBSTANCES USED IN POISONING
4.2 Specific
Injection, 1 mg/ml (sulfate) in 1-ml ampoule 400micrograms/ml. (hydrochloride) in 1 ml ampoule 5. ANTICONVULSANTS/ANTIEPILEPTICS
Injection, 5 mg/ml in 2-ml ampoule (intravenous), Suppository 5mg, Suspension 2mg/5ml Injection, 500 mg/ml in 2-ml ampoule; 500mg/ml in 10-ml ampoule Tablet, 25 mg, 100 mg (sodium salt); Injection, 50 mg/ml in 5-ml vial (sodium salt) Enteric coated tablet, 100mg, 200 mg, (sodium salt); Liquid for oral use 200mg/5ml. 6.ANTI INFECTIVE DRUGS
6.1 Anthelminthics
6.2 Antibacterials
Capsule or tablet, 250 mg, 500 mg (anhydrous); Powder for oral suspension, 125 mg (anhydrous)/5 ml Powder for injection, 500 mg, (as sodium salt) in vial Powder for injection, 1.44 g benzyl penicillin (=2.4 million IU) in 5-ml Powder for injection, 600 mg (= 1 million IU), 3 g (= 5 million IU) Capsule, 500 mg, 1 g (as sodium salt); Powder for oral solution, 125 mg (as sodium salt)/5 ml; Powder for injection, 500 mg (as sodium salt) in vial Capsule, 250 mg; oral suspension, 150 mg (as palmitate)/5 ml; Powder for injection, 1 g (sodium succinate) in vial Tablet 250 mg (as hydrochloride); for (S), Infusion 2mg/ml in 100ml packs; Capsule or tablet, 250 mg, 500 (as stearate) ; Powder for oral suspension, 125 mg/5ml (as stearate); Injection, 10 mg/ml, 40 mg (as sulfate)/ml in 2-ml vial Tablet, 200; 400 mg; injection, 500 mg in 100-ml vial; Oral suspension, 200 mg (as benzoate)/5 ml; Tablets 100mg (hydrochloride)- supplied as part of NLEP Capsule or tablet, 150 mg, 300 mg,450 mg Powder for injection, 1 g (as sulfate) in vial 6.3 Antifungal medicines
Capsule 50 mg; injection 2 mg/ml in vial; Oral suspension 50 mg/5-ml 6.4 Antiviral medicines
Tablet, 200 mg; Powder for injection 250 mg (as sodium salt) in vial Nucleoside reverse transcriptase inhibitors-T 6.5 Antiprotozaol Medicines
6.5.1 Antiamoebic and antigiardiasis medicines Tablet, 200-400 mg; injection, 500 mg in 100-ml vial; Oral suspension 200 mg (as benzoate)/5 ml 6.5.2 Antileishmaniasis medicines – Injection, 30%, equivalent to approximately 8.1% antimony, in 5-ml ampoule -only in districts where problem identified/reported Powder for injection, 200 mg, 300 mg (isetionate) in vial -Only in districts where problem identified/reported Injection 80 mg amp 1 ml amp; capsule 40mg Tablet, 150 mg base (as phosphate or sulfate); Syrup, 50 mg (as phosphate or sulfate)/5 ml; Injection 40 mg (as hydrochloride, phosphate or sulfate)/ml in 5-ml Tablet, 300 mg (as bisulfate or sulfate); Injection, 300 mg/ml. (as dihydrochloride) in 2-ml ampoule 7. ANTIMIGRAINE MEDICINES
7.1 For treatment of acute attack
7.2 For prophylaxis
PALLIATIVE CARE-may be considered for facilities that are designated for cancer

Tablet, 2 mg (hydrochloride); Injection, 5 mg (lactate) in 1-ml 10. MEDICINES AFFECTING THE BLOOD
10.1 Antianaemia medicines
Tablet, equivalent to 65 mg elemental iron (sulfate); Oral solution equivalent to 25 mg iron (as sulfate)/ml Tablet equivalent to 60 mg iron + 400 micrograms folic acid (Nutritional supplement for use during pregnancy.) Tablet 1mg, 5mg; Injection, 1 mg (as sodium salt) in 1-ml ampoule for those areas where SCD is a problem 10.2 Medicines affecting coagulation
Injection, 1000 IU/ml, 5000 IU/ml, 20,000 IU/ml in 1-ml or 5ml ampoule Tablet, 1 mg, 2 mg and 5 mg (sodium salt) 11. BLOOD PRODUCTS AND PLASMA SUBSTITUTES
11.1 Plasma substitutes
Injectable solution, 6% in glucose intrevenous or 5% in 0.9%sodum 11.2 Plasma fractions for specific use –T
12.1 Antianginal medicines
12.2 Antiarrhythmic medicines
Tablet, 62.5 micrograms, 250 micrograms; Oral solution 50 micrograms/ml; Injection 250 micrograms/ml in 2- Injection, 20 mg (hydrochloride)/ml in 5-ml ampoule Tablet, 40 mg, 80 mg (hydrochloride); Injection, 2.5 mg (hydrochloride)/ml in 2-ml ampoule 12.3 Antihypertensive medicines
Hydrochlorothiazide P scored tablet, 25 mg 12.4 Medicines used in heart failure
Tablet, 62.5 micrograms, 250 micrograms; Oral solution, 50 micrograms/ml; Injection, 250 micrograms/ml in 2-ml ampoule Injection, 40 mg (hydrochloride) in 5-ml vial 12.5 Drugs used in Shock/ Eclampsia
13.1 Antifungal medicines
13.2 Anti-infective medicines
Ointment, 5 mg neomycin sulfate + 500 IU bacitracin zinc/g 13.3 Anti-inflammatory and antipruritic medicines
13.5 Medicines affecting skin differentiation and proliferation
13.6 Scabicides and pediculicides
14.1 Ophthalmic medicines
14.2 Radiocontrast media
Injection, 140-420 mg iodine (as sodium or meglumine salt)/ml in 20-ml ampoule Injection 140 –350 mg iodine/ml in 5-ml, 10-ml and 20-ml ampoule Oily suspension, 500-600 mg/ml in 20-ml ampoule (For administration 15. DISINFECTANTS AND ANTISEPTICS
15.1 Antiseptics
15.2 Disinfectants
Powder (0.1% available chlorine) for solution 16. DIURETICS
Tablet, 40 mg ; injection, 10 mg/ml in 2-ml ampoule 17. GASTROINTESTINAL MEDICINES
17.1 Antacids and other anti ulcer medicines
Tablet, 500 mg; Oral suspension 320mg/5ml Tablet 150 mg; 300mg, Injection ( S )50mg/ 2ml. 17.2 Antiemetic medicines
Tablet, 10 mg (hydrochloride); Injection, 5 mg (hydrochloride)/ml in 2-ml ampoule Elixir or syrup, 5 mg (hydrochloride)/5 ml; Injection, 25 mg (hydrochloride)/ml in 2-ml ampoule 17.3 Antihaemorrhoidal medicines
17.4 Anti-inflammatory medicines
Suppository 25 mg (acetate); retention enema Tablet, 500 mg; suppository 500 mg; Retention enema 17.5 Antispasmodic medicines
17.6 Laxatives
17.7 Medicines used in diarrhoea
Powder, 27.9 g/l; Components to reconstitute 1 litre of glucose- sodium chloride 3.5 g/l; trisodium citrate dihydrate* 2.9 g/l; potassium chloride 1.5 g/l; glucose, 20.0 g/l *Trisodium citrate dihydrate may be replaced by sodium bicarbonate (sodium hydrogen carbonate) 2.5g/l. However, as the stability of this latter formulation is very poor under tropical conditions, it is only recommended when manufactured for immediate use. 18. HORMONES, OTHER ENDOCRINE MEDICINES AND CONTRACEPTIVES
18.1 Adrenal hormones and synthetic substitutes
Tablet 500 micrograms, 1mg; injection 4 mg/ml (as phosphate Powder for injection, 100 mg (as sodium succinate) in vial 18.2 Androgens
18.3 Contraceptives
Tablet, 50 micrograms + 250 micrograms (pack of four) 18.4 Estrogens
18.5 Insulins and other antidiabetic agents
Injection, 40 IU/ml in 10-ml vial, 100 IU/ml in 10-ml vial Injection, 40 IU/ml in 10 ml vial; 100 IU/ml in 10 ml vial (as compound insulin zinc suspension or isophane insulin) 18.7 Progestogens
18.8 Thyroid hormones and antithyroid medicines
19.1 Diagnostic agents
All tuberculins should comply with the WHO Requirements for Tuberculins (Revised 1985). WHO Expert Committee on Biological Standardization Thirty-sixth report, (WHO Technical Report Series, No. 745, 1987, Annex 19.2 Sera and immunoglobulins
All plasma fractions should comply with the WHO Requirements for the Collection, Processing and Quality Control of Blood, Blood Components and Plasma Derivatives (Revised 1992). WHO Expert Committee on Biological Standardization Forty-third report, (WHO Technical Report Series, No. 840, 1994, Annex 2). Injection, 50, 100, 300 micrograms/ml in vial 19.3 Vaccines
All vaccines should comply with the WHO Requirements for Biological Substances. 19.3.1 For universal immunization Restrict to medical staff (and spouses of HbsAg carriers) 19.3.2 For specific groups of individuals restricted to areas of high sickle cell disease where indicated RABIES vaccine (inactivated: S Injection,1ml 20. MUSCLE RELAXANTS (PERIPHERALLY ACTING) AND CHOLINESTERASE
Injection, 5 mg (chloride)/ml in 2-ml ampoule Tablet, 15 mg (bromide); Injection, 500 micrograms in 1-ml ampoule; 2.5 mg in 5-ml (metilsulfate) ampoule Injection, 50 mg (chloride)/ml in 2-ml ampoule; powder for injection (chloride), in vial 21. OPHTHALMOLOGICAL PREPARATIONS
21.1 Anti-infective agents
Solution ( eye drops),0.3% w/v sterile aqueous 21.2 Anti-inflammatory agents
Solution, (eye drops), 0.5% (sodium phosphate) 21.3 Local anaesthetics
Solution (eye drops), 0.5% (hydrochloride) 21.4 Miotics and antiglaucoma medicines
Solution (eye drops), 2%, 4% (hydrochloride or nitrate) Solution (eye drops), 0.25%, 0.5% (as maleate) 21.5 Mydriatics
Solution (eye drops), 0.1%; 0.5%, 1% (sulfate) 22.OXYTOCICS AND ANTIOXYTOCICS
22.1 Oxytocics
Tablet, 125 micrograms (hydrogen maleate); Injection, 200 micrograms (hydrogen maleate) in 1-ml ampoule 22.2 Antioxytocics
Tablet 20, 40 mg (hydrochloride), Injection 5mg/ml 23. PERITONEAL DIALYSIS SOLUTION— restricted to tertiary care centre where peritoneal dialysis is
24.1 Medicines used in psychotic disorders
Tablet, 100 mg (hydrochloride); Syrup, 25 mg (hydrochloride)/5ml; Injection, 25 mg (hydrochloride)/ml in 2-ml ampoule Injection, 25 mg (decanoate or enantate) in 1-ml ampoule Tablet, 1.5 mg, 5 mg; Injection, 5 mg in 1-ml ampoule, Liquid 2mg/ml 24.2 Medicines used in mood disorders
24.2.1 Medicines used in depressive disorders 24.2.2 Medicines used in bipolar disorders Enteric coated tablet, 200 mg, (sodium salt) 24.3 Medicines used in generalized anxiety and sleep disorders
25.1 Antiasthmatic medicines
Injection, 1 mg (as hydrochloride or hydrogen tartrate) in 1-ml Syrup, 2 mg/5 ml; Injection, 50 micrograms (as sulfate)/ml in 5-ml ampoule; Solution for use in nebulizers, 5 mg (as sulfate)/ml 25.2 anti tussives and expectorants

26.1 Oral
26.2 Parenteral
Injectable solution, isotonic 5%, 10%; hypertonic 50% Injectable solution, 4% glucose, 0.18% sodium chloride (equivalent to Na+ 30 mmol/l, Cl- 30 mmol/l) Solution, 11.2% in 20-ml ampoule, (equivalent to K+ 1.5 mmol/ml, Injectable solution, 0.9% isotonic (equivalent to Na+ 154 mmol/l, Cl- Injectable solution, 1.4% isotonic (equivalent to Na+ 167 mmol/l, HCO3- 167 mmol/l); solution, 8.4% in 10-ml ampoule (equivalent to 26.3 Miscellaneous
Iodized oil, 1 ml (480 mg iodine) in ampoule (oral or injectable); 0.57 ml (308 mg iodine) in dispenser bottle; Capsule, 200 mg. Capsule, 200 000 IU (as palmitate) (110 mg); Oral oily solution 100 000 IU (as palmitate)/ml in multidose dispenser; Tablet with B1,B2,B6,niacinamide, pantothenate, folic acid, P = Drugs for the Primary Health Centre; Note that all these drugs are therefore by definition part of the essential drug list of secondary and tertiary centres as well. S = Drugs for the community health centre (also known as block PHC), the tehsil level and district level hospitals. P (S.I.) = Specialist Initiated Drugs that may require a specialist consultation or investigation at higher facility to confirm diagnosis before initiating. But once diagnosed the follow up can be taken on a regular basis with the primary health centre. (R) = in very restricted quantities in special situations .



Michael & Michelle Hsieh4325 127th Pl. SEEverett, WA 98208(425) AN OPEN LETTER REGARDING THE DANGERS OF PREPARATION FOR PARENTING ( BABYWISE ) The following is Matthew Hsieh’s history as described by his parents, Michael & Michelle Hsieh,April 1999. The purpose of this letter is to generate public awareness about yet another child who has surel


More information, please In the article, diclofenac gel (Solaraze) is re-You left us hanging! After reading the article byferred to as a “newer topical chemotherapy”Mark E. Meijer, MD, “An unusual approach towhen it is actually considered by most to be aglycemic control” (March 2005), I felt that thenonsteroidal anti-inflammatory drug. In theactual approach was not outlined. Hi

Copyright 2014 Pdf Medic Finder